Sign inJoin waitlistJoin the waitlist

Shiao-Pei Weathers

Section Head, Brain Tumor Section · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

Brain Tumor Section · University of Texas M D Anderson Cancer Center
Present
Brain and Spine Center · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2013–2014
Neurology
University of Michigan
2012–2013
Internal Medicine
Trinity Health Ann Arbor Hospital
2009–2010
Boonshoft School of Medicine - Wright State University
2005–2009

Research

Toward Personalized Targeted Therapeutics: An Overview
Review · Neurotherapeutics · 2017 · First of 2 authors · Corresponding · 20 citations
Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center
European Journal of Cancer · 2019 · 17 citations
Aggressiveness of care at end of life in patients with high-grade glioma
Cancer Medicine · 2021 · 16 citations

Barbara O'Brien
2 papers
Jeffrey Weinberg
2 papers
John de Groot
2 papers
RH
Rebecca Harrison
2 papers · 2 as a fellow
AO
Alexander Ou
1 paper
Carlos Matsuoka
1 paper
Chibawanye Ene
1 paper
DC
David Cachia
1 paper
Eduardo Bruera
1 paper
EG
Eric Goethe
1 paper · 1 as a resident
Frederick Lang
1 paper
Ian McCutcheon
1 paper

Clinical trials

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2023–2027
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Principal investigator · Active not recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2022–2027
Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy
Principal investigator · Active not recruiting
M.D. Anderson Cancer Center
2020–2027
Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2018–2024